Artal Group’s Minerva Neurosciences NERV Stock Holding History

Artal Group’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-250,000	Closed	-$2.31M	–	134
2022 Q3	$2.31M	Buy	+250,000	New	+$1.48M	0.1%	87
2020 Q4	–	Sell	-95,000	Closed	-$2.42M	–	145
2020 Q3	$2.42M	Sell	95,000 -5,000	-5%	-$135K	0.06%	119
2020 Q2	$2.89M	Sell	100,000 -25,000	-20%	-$1.47M	0.08%	119
2020 Q1	$6.02M	Hold	125,000	–	–	0.25%	67
2019 Q4	$7.11M	Hold	125,000	–	–	0.27%	59
2019 Q3	$7.75M	Buy	+125,000	New	+$7.08M	0.31%	58
2018 Q2	–	Sell	-37,500	Closed	-$1.88M	–	114
2018 Q1	$1.88M	Buy	37,500 +6,087	+19%	+$292K	0.02%	96
2017 Q4	$1.52M	Hold	31,413	–	–	0.02%	105
2017 Q3	$1.91M	Hold	31,413	–	–	0.03%	95
2017 Q2	$2.22M	Hold	31,413	–	–	0.04%	95
2017 Q1	$2.04M	Hold	31,413	–	–	0.05%	81
2016 Q4	$2.95M	Buy	31,413 +6,413	+26%	+$655K	0.07%	71
2016 Q3	$2.82M	Buy	+25,000	New	+$2.43M	0.06%	77

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Artal Group's NERV Position: Q4 2022 in Review

Artal Group sold out of Minerva Neurosciences (NERV) in Q4 2022, closing a stake of 250,000 shares — an estimated $2.31M sold.

Artal Group first reported a position in NERV in Q3 2016 and held it in 13 quarters. The position peaked at $7.75M in Q3 2019. 19 funds tracked by Wall St. Rank hold NERV as of Q4 2022.

Artal Group reported no remaining Minerva Neurosciences position as of Q4 2022 after selling out during the quarter.
Artal Group sold 250,000 Minerva Neurosciences shares in Q4 2022, an estimated $2.31M.
Artal Group first reported a position in Minerva Neurosciences in Q3 2016 and held it in 13 quarters.
Artal Group's Minerva Neurosciences position peaked at $7.75M in Q3 2019.
19 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2022.

Based on Artal Group's 13F filing for Q4 2022, filed 13 Feb 2023.